Gene-modified cell therapy: IFNγ/sPD1-engineered BMSCs target lung adenocarcinomas, simultaneously suppressing PI3K/AKT, reducing Tregs by 40%, and inducing tumor senescence via p16 upregulation [269]. The gene discussed is CDKN2A; the disease is neoplasm.